Outcomes of hyperlactatemia on admission in critically ill patients with acute myocardial infarction: A retrospective study from MIMIC-IV

Ting Lu, Liao Tan, Kai Xu, Jia Liu, Chong Liu, Guogang Zhang, Ruizheng Shi, Zheng HuangFrontiers in Endocrinology 2022 · DOI

TL;DR

This study reveals that elevated lactate levels upon admission in critically ill patients with acute myocardial infarction (AMI) are a significant predictor of higher mortality, particularly in the short term. The findings highlight lactate as a crucial, readily available biomarker for risk stratification in this vulnerable patient population, even in the absence of cardiogenic shock or acute heart failure.

What Problem Does This Paper Address?

Acute myocardial infarction (AMI) remains a leading cause of death globally, and critically ill patients with AMI face particularly high mortality rates due to rapid complications. While various biomarkers exist, there's a need for a simple, effective, and readily available indicator to identify "at-risk" patients early for timely intervention. Lactate, a byproduct of glucose metabolism, is known to increase with organ hypoperfusion and is a recognized marker of severity in many critical illnesses. However, its specific role and predictive power for mortality in critically ill AMI patients, especially in large-scale studies, remained unclear. This paper aims to bridge that gap by investigating the correlation between admission hyperlactatemia and various mortality outcomes in this specific patient group.

Methods

This retrospective study utilized data from the Medical Information Mart for Intensive Care (MIMIC-IV) database, a large, publicly available critical care dataset. Patients diagnosed with AMI were included and categorized into four groups based on their serum lactate levels upon admission: normal (≤ 2 mmol/L), mild (>2 to ≤ 5 mmol/L), moderate (>5 to ≤ 10 mmol/L), and severe (>10 mmol/L). The primary outcomes assessed were hospital mortality and mortality over different time points (7-day, 30-day, 1-year, and 5-year). Statistical analyses employed logistic regression and Cox regression models to assess the relationship between lactate levels and mortality, adjusting for potential confounding factors. Kaplan-Meier curves were used to visualize cumulative mortality risk. Subgroup analyses were conducted to examine the association in patients with and without cardiogenic shock or acute heart failure.

Datasets

The study utilized the Medical Information Mart for Intensive Care (MIMIC-IV) v. 2.0 database. This dataset contains de-identified health-related data associated with over 50,000 ICU admissions from adult patients at the Beth Israel Deaconess Medical Center between 2008 and 2019. The paper does not introduce a new dataset or benchmark.

Key Insights and Ideas

  • Lactate as a Universal AMI Risk Marker: The study demonstrates that elevated lactate levels are not just indicative of severe complications like cardiogenic shock but are also a significant predictor of mortality in the broader population of critically ill AMI patients, even those without these specific comorbidities.
  • Dose-Response Relationship: The findings suggest a clear dose-response relationship between lactate levels and mortality risk, with higher lactate concentrations correlating with increased mortality.
  • Short-Term Prognostic Power: Hyperlactatemia, particularly moderate to severe levels, shows a strong association with short-term mortality (hospital, 7-day, and 30-day), highlighting its utility for immediate risk assessment and intervention.
  • Long-Term Implications: While the association with long-term mortality (1-year and 5-year) is also present, it appears to be more pronounced for moderate and severe hyperlactatemia, with mild hyperlactatemia losing its predictive power for these longer timeframes.
  • Inflammation and Hypoperfusion Link: The study hints at the underlying mechanisms, noting that patients with higher lactate levels also exhibited higher SIRS scores and elevated liver transaminases, suggesting a role for inflammation and impaired liver function in contributing to hyperlactatemia in AMI.

Key Results

  • A total of 2171 patients were included in the study.
  • Hospital mortality was significantly higher in patients with hyperlactatemia. Adjusted odds ratios for hospital mortality were:
  • Mild hyperlactatemia: 1.62 (95% CI: 1.20-2.18)
    • Moderate hyperlactatemia: 3.46 (95% CI: 2.15-5.58)
    • Severe hyperlactatemia: 5.28 (95% CI: 2.20-12.70)
  • Short-term mortality (7-day and 30-day) showed a significant upward trend with increasing lactate severity. For example, adjusted hazard ratios for 7-day mortality ranged from 1.99 (mild) to 4.81 (severe).
  • Long-term mortality (1-year and 5-year) was also predicted by moderate and severe hyperlactatemia. Adjusted hazard ratios for 1-year mortality were 2.03 (moderate) and 1.92 (severe), and for 5-year mortality were 1.93 (moderate) and 1.74 (severe).
  • Subgroup analyses indicated that the association between admission lactate and mortality was stable in patients with cardiogenic shock.
  • In patients with acute heart failure, the association with short-term mortality was also stable, but the relationship with 1-year and 5-year mortality was only significant in those without acute heart failure.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Observational Design: This inherent bias means causality cannot be definitively established, and unmeasured confounders may exist.
  • Missing Lactate Values: The study focused on admission lactate, but lactate clearance (changes over time) is also a known prognostic indicator, and its role was not assessed due to data limitations.
  • Generalizability: While MIMIC-IV is a large dataset, it originates from a single medical center, which might limit generalizability to other healthcare settings.

Future work should focus on prospective cohort studies to further validate these findings and explore the prognostic value of lactate clearance in critically ill AMI patients. Investigating the specific mechanisms linking inflammation, catecholamines, and lactate production in AMI would also be beneficial.

Summary updated

Abstract

Hyperlactatemia, especially moderate and severe hyperlactatemia, on admission is closely related to higher short-term mortality incidence in critically ill patients with AMI. The relationship between serum lactate level on admission and short-term mortality of critical AMI patients is stable in subgroups of cardiogenic shock and acute heart failure.
BibTeX
@inproceedings{lu2022outcomes,
  author = {Ting Lu and Liao Tan and Kai Xu and Jia Liu and Chong Liu and Guogang Zhang and Ruizheng Shi and Zheng Huang},
  title = {{Outcomes of hyperlactatemia on admission in critically ill patients with acute myocardial infarction: A retrospective study from MIMIC-IV}},
  booktitle = {Frontiers in Endocrinology},
  year = {2022},
  doi = {10.3389/fendo.2022.1015298},
}
Figure